Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy
- 1 February 1992
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 118 (2) , 163-165
- https://doi.org/10.1007/bf01187507
Abstract
One possible explanation for the failure of the high concentrations of cytotoxic agents achieved following intraperitoneal (i.p.) drug delivery to produce a favorable response in patients with ovarian cancer is the inability of the drug-containing fluid to be adequately distributed throughout the peritoneal cavity, usually because of intraabdominal adhesion formation. To evaluate the influence of the severity of adhesions, observed at the time of laparotomy performed immediately preceding the initiation of i.p. therapy, on the ability to achieve a surgically defined complete response (S-CR), we retrospectively reviewed the operative reports of 70 patients with small-volume residual ovarian cancer treated on one of three phase-2 salvage i.p. trials at the Memorial Sloan-Kettering Cancer Center. The S-CR rate in the 36 patients withlimited adhesion formation observed upon entering the peritoneal cavity was 28%, compared to 35% in the 34 patients withextensive adhesions (P>0.05). In 33 patients treated with a phase-2 cisplatin-based i.p. program, who had previously responded to systemic platinum, 47% (8/17) and 44% (7/16) of those with limited and extensive adhesions, respectively, achieved a S-CR (P>0.05). We conclude that the presence of extensive adhesions observed within the peritoneal cavity at the time of a laparotomy performed immediately prior to the initiation of i.p. therapy does not have a negative impact on the potential to achieve an S-CR, assuming it is technically feasible to lyse all significant adhesions prior to the completion of the operative procedure.Keywords
This publication has 10 references indexed in Scilit:
- Intraperitoneal ChemotherapyPublished by Elsevier ,2003
- Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.Journal of Clinical Oncology, 1991
- Intraperitoneal chemotherapy.1991
- Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.Journal of Clinical Oncology, 1991
- Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.Journal of Clinical Oncology, 1990
- Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.Journal of Clinical Oncology, 1989
- Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavityCancer Treatment Reviews, 1986
- Intraperitoneal Cisplatin with Systemic Thiosulfate ProtectionAnnals of Internal Medicine, 1982
- Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamicsAmerican Journal of Roentgenology, 1979
- The effect of volume on the distribution of substances instilled into the peritoneal cavityGynecologic Oncology, 1978